DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, YM | - |
dc.contributor.author | Park, O | - |
dc.contributor.author | Swierczewska, M | - |
dc.contributor.author | Hamilton, JP | - |
dc.contributor.author | Park, JS | - |
dc.contributor.author | Kim, TH | - |
dc.contributor.author | Lim, SM | - |
dc.contributor.author | Eom, H | - |
dc.contributor.author | Jo, DG | - |
dc.contributor.author | Lee, CE | - |
dc.contributor.author | Kechrid, R | - |
dc.contributor.author | Mastorakos, P | - |
dc.contributor.author | Zhang, C | - |
dc.contributor.author | Hahn, SK | - |
dc.contributor.author | Jeon, OC | - |
dc.contributor.author | Byun, Y | - |
dc.contributor.author | Kim, K | - |
dc.contributor.author | Hanes, J | - |
dc.contributor.author | Lee, KC | - |
dc.contributor.author | Pomper, MG | - |
dc.contributor.author | Gao, B | - |
dc.contributor.author | Lee, S | - |
dc.date.accessioned | 2017-07-19T12:49:56Z | - |
dc.date.available | 2017-07-19T12:49:56Z | - |
dc.date.created | 2016-09-29 | - |
dc.date.issued | 2016-07 | - |
dc.identifier.issn | 0270-9139 | - |
dc.identifier.uri | https://oasis.postech.ac.kr/handle/2014.oak/36513 | - |
dc.description.abstract | Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma. No US Food and Drug Administration-approved targeted antifibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aHSCs, while preserving quiescent HSCs and other normal cells, is a logical strategy to stop and/or reverse liver fibrogenesis/fibrosis. However, there are no effective approaches to specifically deplete aHSCs during fibrosis without systemic toxicity. aHSCs are associated with elevated expression of death receptors and become sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death. Treatment with recombinant TRAIL could be a potential strategy to ameliorate liver fibrosis; however, the therapeutic application of recombinant TRAIL is halted due to its very short half-life. To overcome this problem, we previously generated PEGylated TRAIL (TRAIL(PEG)) that has a much longer half-life in rodents than native-type TRAIL. In this study, we demonstrate that intravenous TRAILPEG has a markedly extended half-life over native-type TRAIL in nonhuman primates and has no toxicity in primary human hepatocytes. Intravenous injection of TRAILPEG directly induces apoptosis of aHSCs in vivo and ameliorates carbon tetrachloride-induced fibrosis/cirrhosis in rats by simultaneously down-regulating multiple key fibrotic markers that are associated with aHSCs. Conclusion: TRAIL-based therapies could serve as new therapeutics for liver fibrosis/cirrhosis and possibly other fibrotic diseases. | - |
dc.language | English | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.relation.isPartOf | HEPATOLOGY | - |
dc.title | Systemic PEGylated TRAIL Treatment Ameliorates Liver Cirrhosis in Rats by Eliminating Activated Hepatic Stellate Cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/HEP.28432 | - |
dc.type.rims | ART | - |
dc.identifier.bibliographicCitation | HEPATOLOGY, v.64, no.1, pp.209 - 223 | - |
dc.identifier.wosid | 000379233400025 | - |
dc.date.tcdate | 2019-02-01 | - |
dc.citation.endPage | 223 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 209 | - |
dc.citation.title | HEPATOLOGY | - |
dc.citation.volume | 64 | - |
dc.contributor.affiliatedAuthor | Hahn, SK | - |
dc.identifier.scopusid | 2-s2.0-84976498736 | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.wostc | 15 | - |
dc.description.scptc | 10 | * |
dc.date.scptcdate | 2018-05-121 | * |
dc.type.docType | Article | - |
dc.subject.keywordPlus | APOPTOSIS-INDUCING LIGAND | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | TOXICITY | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
library@postech.ac.kr Tel: 054-279-2548
Copyrights © by 2017 Pohang University of Science ad Technology All right reserved.